Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Surgical Dermatology Group, Birmingham, Alabama.
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
J Am Acad Dermatol. 2020 Mar;82(3):634-641. doi: 10.1016/j.jaad.2019.07.040. Epub 2019 Jul 22.
Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma.
To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma.
Retrospective, single-institution review of outcomes for skin-directed radiation therapy.
Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation.
Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number).
Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.
局部或全身皮肤放射疗法可用于治疗轻至难治性皮肤 T 细胞淋巴瘤。
报告放射疗法治疗皮肤 T 细胞淋巴瘤的广泛疗效。
回顾性、单机构皮肤定向放射治疗结果分析。
皮肤定向放射治疗后，无论受累情况、严重程度、组织病理学亚型、剂量或分割如何，其反应率为 99%，完全缓解率为 80%。总野内复发率为 15%，中位复发时间为 296 天（范围 1-1884 天）。局部和低分割方案与疾病反应和罕见毒性同样相关。治疗后继发皮肤癌的短期发生率与无放疗患者人群的预期发生率相当。
与患者总数相比，治疗方案的总数非常多。治疗方案（剂量或分割次数无标准化）混杂。
对于适当选择的皮肤 T 细胞淋巴瘤患者，放射疗法是一种耐受良好的治疗选择。
